(Q37432527)

20 August 2017

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma (English)

1 reference

20 August 2017

0 references

1 reference

5

Mark Munsell

1 reference

20 August 2017

2

Karen H Lu

1 reference

20 August 2017

10

David M Gershenson

1 reference

20 August 2017

1

Brian M Slomovitz

1 reference

20 August 2017

Taren Johnston

3

1 reference

20 August 2017

Robert L Coleman

4

1 reference

20 August 2017

Russell R Broaddus

6

1 reference

20 August 2017

Cheryl Walker

7

1 reference

20 August 2017

Lois M Ramondetta

8

1 reference

20 August 2017

Thomas W Burke

9

1 reference

20 August 2017

Judith Wolf

11

1 reference

20 August 2017

language of work or name

English

0 references

publication date

2 August 2010

1 reference

20 August 2017

1 reference

20 August 2017

116

1 reference

20 August 2017

23

1 reference

20 August 2017

5415-5419

1 reference

The TOR pathway: a target for cancer therapy

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5120730

Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20681032

12 December 2020

inferred from PubMed ID database lookup

PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20681032

12 December 2020

inferred from PubMed ID database lookup

Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20681032

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/CNCR.25515

1 reference

release_dixlsfywzjdjdeomvehqrftr4u

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dixlsfywzjdjdeomvehqrftr4u

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

1 reference